Home
HelpTest Code JAK2B JAK2 V617F Mutation Detection, Blood
Reporting Name
JAK2 V617F Mutation Detection, BUseful For
Aiding in the distinction between a reactive blood cytosis and a chronic myeloproliferative disorder using peripheral blood specimens
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Whole Blood EDTAShipping Instructions
Specimen must arrive within 7 days of collection.
Specimen Required
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood EDTA | Ambient (preferred) | 7 days | PURPLE OR PINK TOP/EDTA |
| Refrigerated | 7 days | PURPLE OR PINK TOP/EDTA |
Special Instructions
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Saturday
CPT Code Information
81270-JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| JAK2B | JAK2 V617F Mutation Detection, B | 43399-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 39722 | JAK2 Result | 53761-3 |
| 29590 | JAK2 V617F Mutation Detection, B | 43399-5 |
Testing Algorithm
For more information see:
-Erythrocytosis Evaluation Testing Algorithm
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Report Available
2 to 5 daysReject Due To
| Gross hemolysis | Reject |
| Moderately to severely clotted | Reject |
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Method Name
Quantitative Polymerase Chain Reaction (PCR)